NEW FOR 2024
Introducing the Pharmacology Seminar Day Stream
Introducing the Pharmacology Seminar Day Stream Underpinned by the recent FDA guidance on designing clinical pharmacology studies for ADCs, this brand-new seminar day is designed for ADC experts working in PK/PD and clinical pharmacology. Led by leaders from Novartis, SOTIO Biotech, ADC Therapeutics, Vincerx Pharma, Pfizer and Gilead Sciences, explore ADC pharmacodynamic markers and modeling, early clinical dose optimization and best practices for ADC pharmacology strategy to inform successful ADC clinical performance
Novel Biopharma Speakers
With the largest speaker faculty to date and over 85 new speakers on the program, learn from first-time presenting biotechs ABL Bio, Angiex, Huadong Medicine, Multitude Therapeutics, Mythic Therapeutics, and Oxford Biotherapeutics; as well as oncology leaders from new big pharma on the scene, Pfizer and Ipsen. They will deliver end-to-end content and insights spanning Degrader Antibody Conjugates, Bispecific ADCs, ADC target discovery, early clinical dosing, managing supply chain ahead of IND submission, and weighing up internal vs. outsourced manufacturing
Exclusive Panel Session: Diversity & Inclusion in Oncology & ADC Clinical Trials*
Ensuring D&I in clinical trials is crucial to encompass the broad range of lived experiences and diverse populations so that all patients can benefit from ADC clinical advances. Led by D&I experts from Merck & Co, Equity Bridge and TOUCH, The Black Breast Cancer Alliance, attend this panel session to explore the significance of D&I in ADC development, understand the patient perspective, and hear successful case studies of implementing patient considerations in clinical trial design and recruitment.
* Available for all attendees.
After Pre-Conference Seminar Day | Monday, November 4, 2024 I 3.30pm
Panel Session: Diversity & Inclusion in Oncology & ADC Clinical Trials
Attend this brand-new session led by oncology D&I leaders to explore the significance and importance of D&I in ADC development, learn from mistakes in the past, and hear case studies on developing and implementing robust D&I policies in clinical trial design and recruitment to ensure your ADC product development is representative to all patient populations.
Register your interest when you sign up to attend the conference, then look out for an email to secure your spot!
Highlights include:
- Exploring the current status and opportunities for improvement in D&I throughout ADC product development – what mistakes have been made in the past?
- Hearing case studies and company strategies to address and improve D&I in ADC clinical trials
- Explaining the clinical trial design and recruitment considerations from the beginning to make ADC products representative to all patient populations
- Breaking down takeaways of lived experience and incorporating learnings to help design ADC clinical trials Moderators
Moderators:
